AR106977A1 - Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral - Google Patents

Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral

Info

Publication number
AR106977A1
AR106977A1 ARP160103818A ARP160103818A AR106977A1 AR 106977 A1 AR106977 A1 AR 106977A1 AR P160103818 A ARP160103818 A AR P160103818A AR P160103818 A ARP160103818 A AR P160103818A AR 106977 A1 AR106977 A1 AR 106977A1
Authority
AR
Argentina
Prior art keywords
amylooid
angiopathy
cerebral
alzheimer
disease
Prior art date
Application number
ARP160103818A
Other languages
English (en)
Inventor
Boyd Robert
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR106977A1 publication Critical patent/AR106977A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto que tiene una estructura representada por la fórmula (1) ó (2), donde: R¹, R², R⁴ se seleccionan independientemente entre H, alquilo C₁₋₈, arilo, (CH₂)ₙ-arilo, (CH₂)ₙ-heteroarilo; n = 0 - 8; X¹, X² se seleccionan independientemente entre CO, SO, SO₂, -CONH-, SO₂NH-, SONH-; y A¹, A², B¹, B², C¹, C² se seleccionan independientemente entre H, OR⁴, F, con la salvedad de que el compuesto no es 2-acetamido-1,2-didesoxinojirimicina o 2-acetamido-1,2-didesoxigalactonojirimicina, o una de sus sales, solvatos o profármacos farmacéuticamente aceptables.
ARP160103818A 2015-12-14 2016-12-13 Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral AR106977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266760P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
AR106977A1 true AR106977A1 (es) 2018-03-07

Family

ID=59018347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103818A AR106977A1 (es) 2015-12-14 2016-12-13 Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral

Country Status (9)

Country Link
US (3) US9994589B2 (es)
EP (1) EP3390408A1 (es)
JP (1) JP2019502679A (es)
CN (1) CN108368131A (es)
AR (1) AR106977A1 (es)
AU (1) AU2016371917A1 (es)
CA (1) CA3008266A1 (es)
TW (1) TW201725197A (es)
WO (1) WO2017106288A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3722788A1 (de) * 1987-07-10 1989-01-19 Bayer Ag Chirale 6-hydroxymethylenverzweigte 3-amino-4,5-dihydroxypiperidine, zwischenprodukte zu ihrer herstellung, verfahren zu ihrer herstellung und ihre verwendung
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
PL2490712T3 (pl) 2009-10-19 2015-12-31 Amicus Therapeutics Inc Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz
CA2822493C (en) * 2010-12-23 2018-11-20 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012159262A1 (en) * 2011-05-24 2012-11-29 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
JP6147737B2 (ja) * 2011-06-27 2017-06-14 アレクトス・セラピューティクス・インコーポレイテッド 選択的グリコシダーゼ阻害剤およびその使用
US9522883B2 (en) * 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses

Also Published As

Publication number Publication date
US20190135832A1 (en) 2019-05-09
TW201725197A (zh) 2017-07-16
US20180291037A1 (en) 2018-10-11
EP3390408A1 (en) 2018-10-24
WO2017106288A1 (en) 2017-06-22
US9994589B2 (en) 2018-06-12
US10793583B2 (en) 2020-10-06
CA3008266A1 (en) 2017-06-22
AU2016371917A1 (en) 2018-06-28
US20170166588A1 (en) 2017-06-15
JP2019502679A (ja) 2019-01-31
CN108368131A (zh) 2018-08-03
US10174054B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
BR112017006253A2 (pt) novos compostos
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
JOP20170107B1 (ar) مشتقات سلفوناميد عطرية
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CU24435B1 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CO2019011967A2 (es) Compuestos antitumorales
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR104415A1 (es) Compuestos antiestrogénicos derivados de cromeno
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR095523A1 (es) Derivados piridin-4-ilo
AR103742A1 (es) Derivados de trifluorometilpropanamida
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
PE20190376A1 (es) Combinaciones farmaceuticas para el tratamiento del cancer
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2020000376A1 (es) Compuesto pentacíclico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure